Success Metrics

Clinical Success Rate
93.8%

Based on 30 completed trials

Completion Rate
94%(30/32)
Active Trials
2(6%)
Results Posted
40%(12 trials)
Terminated
2(6%)

Phase Distribution

Ph phase_4
5
15%
Ph phase_3
3
9%
Ph not_applicable
8
24%
Ph phase_1
11
32%
Ph phase_2
3
9%

Phase Distribution

11

Early Stage

3

Mid Stage

8

Late Stage

Phase Distribution30 total trials
Phase 1Safety & dosage
11(36.7%)
Phase 2Efficacy & side effects
3(10.0%)
Phase 3Large-scale testing
3(10.0%)
Phase 4Post-market surveillance
5(16.7%)
N/ANon-phased studies
8(26.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.8%

30 of 32 finished

Non-Completion Rate

6.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

34

all time

Status Distribution
Active(2)
Completed(30)
Terminated(2)

Detailed Status

Completed30
Recruiting2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
34
Active
2
Success Rate
93.8%
Most Advanced
Phase 4

Trials by Phase

Phase 111 (36.7%)
Phase 23 (10.0%)
Phase 33 (10.0%)
Phase 45 (16.7%)
N/A8 (26.7%)

Trials by Status

completed3088%
recruiting26%
terminated26%

Recent Activity

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT03511118

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting
NCT05211050Not Applicable

Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine

Completed
NCT06503848

Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

Recruiting
NCT05108688Phase 4

Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache

Completed
NCT00620425Phase 1

A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site Signs

Completed
NCT05654298Not Applicable

Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin

Completed
NCT01430442Phase 2

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

Completed
NCT01632657Not Applicable

Effect of Sumatriptan on the Postoperative Quality of Recovery After Elective Minimally Invasive Craniotomy

Completed
NCT00892203Phase 2

Efficacy and Safety of BGG492 in the Treatment of Migraine

Completed
NCT04197349Phase 1

Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman

Completed
NCT04355845Phase 1

A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.

Completed
NCT00804973Phase 2

Study in Participants With Acute Migraines Headaches

Terminated
NCT03585894Not Applicable

The Role of Inflammation and Vasodilatation in PACAP38-induced Headache Using MRI on Healthy Subjects

Completed
NCT03076970Phase 1

Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants

Completed
NCT03310411Phase 1

A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants

Completed
NCT02932488Phase 1

Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation

Terminated
NCT02741310Phase 1

Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan

Completed
NCT00701389Phase 1

Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)

Completed
NCT01071317Phase 4

Trial of Comprehensive Migraine Intervention

Completed
NCT03156920Not Applicable

Pretreatment With Sumatriptan on Cilostazol Induced Headache in Healthy Volunteers

Completed

Drug Details

Intervention Type
DRUG
Total Trials
34